valproate + clonazepam

Valproate + clonazepam is a combination of two antiepileptic drugs used primarily in the management of epilepsy and certain treatment-resistant neuropsychiatric conditions. Valproate (also known as sodium valproate or valproic acid) is a broad-spectrum anticonvulsant that increases brain levels of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by inhibiting GABA transaminase and succinic semialdehyde dehydrogenase, leading to enhanced inhibitory neurotransmission. It may also suppress voltage-gated sodium channels and modulate intracellular signaling pathways involved in neural plasticity[7][6]. Clonazepam is a benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, enhancing the effect of GABA at this receptor and producing anticonvulsant, anxiolytic, sedative, and muscle relaxant effects[6]. The combination has been used for refractory epilepsy (including progressive myoclonus epilepsy) and treatment-resistant panic disorder when monotherapy fails[2][3][8]. However, co-administration can increase central nervous system depression—manifesting as severe drowsiness or muscle weakness—and should be monitored closely due to potential drug interactions[1][5].

Brand names

DepakoteDepakeneKlonopinRivotril

Other names

sodium valproate + clonazepamvalproic acid + clonazepam